Danaher Corporation $DHR Stock Acquired by Ninety One UK Ltd

Posted by Brenda Bartman on Oct 16th, 2026

Ninety One UK Ltd boosted its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 22.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,880 shares of the conglomerate’s stock after acquiring an additional 11,890 shares during the quarter. Ninety One UK Ltd’s holdings in Danaher were worth $14,374,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in DHR. BlackRock Inc. acquired a new stake in Danaher during the second quarter valued at approximately $10,492,520,000. Jupiter Topco LLC bought a new stake in shares of Danaher in the 2nd quarter valued at approximately $1,456,317,000. Generation Investment Management LLP bought a new stake in shares of Danaher in the 2nd quarter valued at approximately $1,287,949,000. Bank of America Corp DE bought a new stake in shares of Danaher in the 2nd quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc acquired a new position in shares of Danaher in the 2nd quarter worth approximately $801,056,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analyst Ratings Changes

DHR has been the subject of several analyst reports. Evercore restated an “outperform” rating and set a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Barclays boosted their price target on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. The Goldman Sachs Group upped their price target on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Morgan Stanley increased their price objective on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Royal Bank Of Canada increased their price objective on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Check Out Our Latest Report on Danaher

Danaher Price Performance

NYSE:DHR opened at $231.52 on Friday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a market cap of $162.76 billion, a PE ratio of 41.12, a price-to-earnings-growth ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company’s 50-day moving average price is $213.55 and its two-hundred day moving average price is $195.74.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the business posted $0.77 earnings per share. The company’s revenue was up 5.5% on a year-over-year basis. On average, equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is 28.42%.

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.